Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators

Pharmacology and Therapeutics

Volumn 78, Issue 3, 1998, Pages 141-154

  Killion, Jerald J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunomodulators; Liposomes; Macrophage activation; Metastasis; Muramyl tripeptide

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT INTERLEUKIN 2; S (2,3 DIDODECANOYLOXYPROPYL) N HEXADECANOYLCYSTEINYLALANYL DEXTRO ISOGLUTAMINYLGLYCYLTAURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; ENCAPSULATION; HUMAN; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG METASTASIS; MACROPHAGE ACTIVATION; METASTASIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; CLINICAL TRIALS; DRUG CARRIERS; HUMANS; IMMUNOTHERAPY; LIPOSOMES; MACROPHAGE ACTIVATION; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0031780528     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00004-7     Document Type: Review

References (135)

1. Acero R., Polentaretti N., Boffazzi H., Alberti S., Rizza A., Mantovani A. Effect of hydrocortisone on the macrophage content, growth, and metastases of transplanted murine tumors. Int. J. Cancer. 33:1984;95-100.
2. Allison A.C. On the role of mononuclear phagocytes in immunity against viruses. Prog. Med. Virol. 18:1974;15-31.
3. Altomonte M., Gloghini A., Bertola G., Gasparollo A., Carbone A., Ferrone S., Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53:1993;3343-3348.
4. Alving C.R. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol. Rev. 22:1983;407-424.
5. Asano T., Kleinerman E.S. Liposome-encapsulated MTP-PE. a novel biologic agent for cancer therapy J. Immunother. 14:1993;286-292.
6. Berasconi S., Matteucci C., Sironi M., Conni M., Colotta F., Mosca M., Colombo N., Bonazzi C., Landoni F., Corbetta G., Mantovani A., Allavena P. Effects of granulocyte-monocyte colony-stimulating factor (Gm-csf) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int. J. Cancer. 60:1995;300-307.
7. Bishop M.J. The molecular genetics of cancer. Science. 235:1987;305-311.
8. Brodey R.S., Abt D.A. Results of surgical treatment in 65 dogs with osteosarcoma. J. Am. Vet. Med. Assoc. 168:1976;1032-1038.
9. Brodt P., Blore J., Philips N.C., Munzer J.S., Rioux J.D. Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. Cancer Immunol. Immunother. 28:1989;54-60.
10. Brunda M.J., Wiltrout R.H., Holden H.T., Baresio L. Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines, and natural killer cells. Int. J. Cancer. 31:1983;373-379.
11. Bucana C.D., Fabra A., Sanchez R., Fidler I.J. Different patterns of macrophage infiltration into allogeneic murine and xenogeneic human neoplasms growing in nude mice. Am. J. Pathol. 141:1992;1125-1236.
12. Bugelski P.J., Kirsh R., Poste G. New histochemical method for measuring intratumoral macrophages and macrophage recruitment into experimental metastases. Cancer Res. 43:1983;5493-5501.
13. Bugelski P.J., Cotwon S.P., North S.M., Kirsh R., Nicolson G.M., Poste G. Macrophage content of spontaneous metastases at different stages of growth. Cancer Res. 47:1987;4141-4147. a.
14. Bugelski P.J., Kirsh R., Ruscarmo C., Cotwin S.P., Poste G. Recruitment of exogeneous macrophages into metastases at different stages of tumor growth. Cancer Immunol. Immunother. 24:1987;93-98. b.
15. Chabner, B. A. and Meyers, C. E. (1989) Clinical pharmacology of cancer chemotherapy. In: Cancer, Principles and Practice of Oncology, pp. 349-395, DeVita, V. T., Jr., Hellman, S. and Rosenberg, S. A. (eds.) J. B. Lippincott Co., Philadelphia.
16. Chedid L., Audibert F., Johnson A.G. Biological activities of muramyl depeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog. Allergy. 25:1978;63-80.
17. Connor J., Bucana C.D., Fidler I.J., Schroit A.J. Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes. quantitative assessment of outer leaflet lipid by prothrombinase complex formation Proc. Natl. Acad. Sci. USA. 86:1989;3184-3188.
18. Crawford R.M., Finbloom D.S., Ohara J., Paul W.E., Meltzer M.S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J. Immunol. 135:1987;135-141.
19. Creaven P.J., Cowens J.W., Brenner D.E., Dadey B.M., Han T., Buben R., Karakousis C., Frost H., LeSher D., Hanagan J., Andrejcio K., Cushman M.K. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J. Biol. Response Modif. 9:1990;492-498.
20. Deodhar S.D., James K., Chiang T., Barna B.P. Inhibition of lung metastasis in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 42:1982;5084-5091.
21. Dinney C.P.N., Bucana C.D., Utsugi T., Fidler I.J., von Eschenbach A.C., Killion J.J. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res. 51:1991;3741-3747.
22. Dinney C.P.N., Utsugi T., Fidler I.J., von Eschenbach A.C., Killion J.J. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or γ-interferon. Cancer Res. 52:1992;1155-1161.
23. Dong Z., Qi X., Fidler I.J. Tyrosine phosphorylation of mitogen-activated protein kinsases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J. Exp. Med. 177:1993;1071-1077.
24. Eppstein D.A., Van der Pas M.A., Fraser-Smith E.B. Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int. J. Immunother. 2:1986;115-126.
25. Espinoza-Delgado I., Bosco M.C., Musso T., Gusella G.L., Longo D.L., Varesio L. Interleukin-2 and human monocyte activation. J. Leukoc. Biol. 57:1995;13-19.
26. Evans R. Macrophages and neoplasms. new insights and their implications in tumor immunobiology Cancer Metastasis Rev. 1:1982;227-243.
27. Evans R., Cullen R.T. In situ proliferation of intratumor macrophages. J. Leukoc. Biol. 35:1984;561-568.
28. Evans R., Lawlor E. Macrophage content and immunogenicity of C57BL/6 and BALB/c ByJ methycholanthrene-induced sarcomas. Int. J. Cancer. 26:1980;831-837.
29. Fialkow P.J. Clonal origin of human tumors. Annu. Rev. Med. 30:1979;135-176.
30. Fidler I.J. Therapy of spontaneous metastasis by intravenous injection of liposome containing lymphokines. Science. 208:1980;1469-1471.
31. Fidler, I. J. (1986a) Immunomodulation of macrophages for cancer and antiviral therapy. In: Site-Specific Drug Delivery, pp. 111-135, Tomlinson, E. and Davis, S. S. (eds.) John Wiley, New York.
32. Fidler I.J. Optimization and limitations of systemic treatment of murine melanoma metastasis with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother. 21:1986;169-173. b.
33. Fidler I.J. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Delivery Rev. 1:1988;69-106.
34. Fidler I.J. Critical factors in the biology of human cancer metastasis. twenty-eighth G.H.A. Clowes memorial award lecture Cancer Res. 50:1990;6130-6138.
35. Fidler I.J., Balch C.M. The biology of cancer metastasis and implications for therapy. Curr. Prob. Surg. 24:1987;131-233.
36. Fidler I.J., Cifone M.A. Properties of metastatic and nonmetastatic cloned sunpopulations of an ultraviolet light-induced murine fibrosarcoma of recent origin. Am. J. Pathol. 97:1979;633-648.
37. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
38. Fidler I.J., Hart R.I. Biological diversity in metastatic neoplasms. origins and implications Science. 217:1982;998-1003.
39. Fidler I.J., Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin. Immunopathol. 5:1982;161-174.
40. Fidler I.J., Schroit A.J. Synergism betwen lymphokine and muramyl dipeptide encapsulated in liposomes. in situ activation of macrophages and therapy of spontaneous cancer metastasis J. Immunol. 133:1984;515-518.
41. Fidler I.J., Schroit A.J. Recognition and destruction of neoplastic cells by activated macrophages. discrimination of altered self Biochim. Biophys. Acta. 948:1988;151-173.
42. Fidler I.J., Raz A., Fogler W.E., Kirsh R., Bugelski P., Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 40:1980;4460-4466.
43. Fidler I.J., Sone S., Fogler W.E., Barnes Z.L. Eradication of spontaneous metastasis and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. USA. 78:1981;1680-1684.
44. Fidler I.J., Sone S., Fogler W.E., Smith D., Braun D.G., Tarcsay L., Gisler R.H., Schroit A.J. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J. Biol. Response Modif. 1:1982;43-55.
45. Fidler I.J., Fogler W.E., Tarcsay L., Schumnann G., Graun D.G., Schroit A.J. Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. Immunopharmacology. 2:1983;235-253.
46. Fidler I.J., Jessup J.M., Fogler W.E., Staerkel R., Mazumder A. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res. 46:1986;994-998.
47. Fidler I.J., Fogler W.E., Brownbill A.F., Schumann G. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J. Immunol. 138:1987;4509-4514.
48. Fidler I.J., Fan D., Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis. 9:1989;75-88.
49. Fidler I.J., Nii A., Utsugi T., Brown D., Bakouche O., Kleinerman E.S. Differential release of TNF-α, IL1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res. 9:1990;449-463.
50. Fogler, W. E. and Fidler, I. J. (1984) Modulation of the immune response by muramyl depeptide. In: Immunomodulation Agents and Their Mechanisms, pp. 499-512, Chirigos, M. A. and Fenichel, R. L. (eds.) Marcel Dekker, New York.
51. Fogler W.E., Fidler I.J. Nonselective destruction of murine macrophages by syngeneic tumoricidal macrophages. Cancer Res. 45:1985;14-18.
52. Fogler W.E., Fidler I.J. The activation of tumoricidal properties in human blood monocytes by muramyl peptides requires a specific intracellular interaction. J. Immunol. 136:1986;2311-2316.
53. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
54. Garcia-Prado A., Ferreira O.C., Valinsky J., Biano C. Fibronectin receptors of mononuclear phagocytes. binding characteristics and biochemical isolation Exp. Cell Res. 181:1989;420-431.
55. Gillete, E. L. (1982) Spontaneous canine neoplasms as models for therapeutic agents. In: Design of Models for Testing Cancer Therapeutic Agents, pp. 185-192, Fidler, I. J. and White, R.J. (eds.) Van Nostrand-Reinhold, New York.
56. Gisler, R. H., Dietrich, F. M., Baschang, G., Brownbill, A., Schumann, G., Staber, F. G., Tarcsay, L., Wachsmuth, E. D. and Dukor, P. (1979) New developments in drugs enhancing the immune response: activation of lymphocytes and accessory cells by muramyl-dipeptides. In: Drug and Immune Responsiveness, pp. 133-160, Turk, J. L. and Danker, D. (eds.) University Park Press, Baltimore.
57. Gjoen T., Seljelid R., Kolset S.O. Binding of metastatic colon carcinoma cells to liver macrophages. J. Leukoc. Biol. 45:1989;362-369.
58. Gordesky S.E., Marinetti G.V. The asymmetric arrangement of phospholipids in the human erythrocyte membrane. Biochem. Biophys. Res. Commun. 50:1973;1027-1031.
59. Gordon S., Perry V.H., Rabinowitz S., Chung L., Rosen H. Plasma membrane receptors of the mononuclear phagocyte system. J. Cell Sci. 9:1988;1-26.
60. Heppner G. Tumor heterogeneity. Cancer Res. 44:1984;2259-2265.
61. Hibbs J.B. Jr. Discrimination between neoplastic and nonneoplastic cells in vitro by activated macrophages. J. Natl. Cancer Inst. 53:1974;1487-1492. a.
62. Hibbs J.B. Jr. Heterocytolysis by macrophages activated by bacillus Calmette-Guerin. lysosome exocytosis into tumor cells Science. 184:1974;468-471. b.
63. Hibbs J.B. Jr., Lambert L.H., Remington J.S. Control of carcinogenesis. a possible role for the activated macrophage Science. 177:1972;998-1000.
64. Hisano G., Fidler I.J. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol. Immunother. 14:1990;61-66.
65. Hori K., Mihich E., Ehrike M.J. Role of tumor necrosis factor and interluekin 1 in γ-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res. 49:1989;2606-2614.
66. Huard T.K., Raney J.I., Wood J.F.B., Wieha M.A. A potential role for the extracellular matrix glycoprotein lamminin on macrophage-tumor cell interactions. Int. J. Cancer. 36:1985;511-517.
67. Hudson M.M., Snyder J.S., Jaffe N., Kleinerman E.S. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res. 48:1988;5256-5263.
68. r 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int. J. Cancer. 58:1994;582-586.
69. Ijiri K., Potten C.S. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br. J. Cancer. 47:1983;175-183.
70. Kerbel R.S. Implications of immunological heterogeneity in tumors. Nature. 280:1979;358-360.
71. Killion J.J. Immunotherapy with tumor subpopulations. II. Therapy of drug-resistant L1210 leukemia and El4 lymphoma. Cancer Immunol. Immunother. 5:1979;21-26:
72. Killion J.J., Fidler I.J. The biology of tumor metastasis. Semin. Oncol. 16:1989;106-115.
73. Killion J.J., Kollmorgen G.M. Isolation of immunogenic tumor cells by cell-affinity chromatography. Nature. 259:1976;674-676.
74. Killion J.J., Kleinerman E.S., Wilson M.R., Tanaka M., Fidler I.J. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide. determination of potential interactions between these agents Oncol. Res. 4:1992;413-418.
75. Killion J.J., Radinsky R.R., Dong Z., Fishbeck R., Whitworth P., Fidler I.J. The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype. Cancer Immunol. Immunother. 36:1993;381-386.
76. Killion J.J., Brown D.R., Wilson M.R., Lloyd M.M., Fidler I.J. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide. Oncol. Res. 6:1994;357-364.
77. Killion J.J., Bucana C.D., Radinsky R., Dong Z., O'Reilly T., Bilbe G., Tarcsay L., Fidler I.J. Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine. Cancer Biother. Radiopharmacol. 11:1996;363-371.
78. Killion, J. J., Kleinerman, E. S. and Fidler, I. J. (1997) Induction of lung macrophage tumoricidal activity by liposome-mediated delivery of synthetic macrophage activators. In: Lung Macrophages and Dendritic Cells, pp. 693-723, Lipscomb, M. F. and Russell, S. (eds.) Marcel Dekker, New York.
79. Kleinerman E.S., Fidler I.J. Production and utilization of human lymphokines containing macrophage-activating factor (Maf) activity. Lymphokine Res. 2:1983;7-12:
80. Kleinerman E.S., Erickson K.L., Schroit A.J., Fogler W.E., Fidler I.J. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 43:1983;2010-2014.
81. Kleinerman E.S., Raymond A.K., Bucana C.D., Jaffe N., Harris M.B., Krakoff I.H., Benjamin R., Fidler I.J. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. 34:1992;211-220.
82. Kleinerman E.S., Meyers P.A., Raymond A.K., Gano J.B., Jia S.F., Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide. tolerability, toxicity, and immune stimulation J. Immunother. 17:1995;181-193.
83. Lederer E. Synthetic immunostimulants derived from the bacterial cell wall. J. Med. Chem. 23:1980;819-825.
84. Ling P.D., Warren M.K., Vogel S.N. Antagonistic effect of interferon-β on the interferon-τ-induced expression of Ia antigen in murine macrophages. J. Immunol. 135:1985;1857-1863.
85. Lopez-Berestein G., Milas L., Hunter N., Mehta E., Eppstein D., Van der Pas M.A., Mathews T.R., Hersh E.M. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-0-steroyl-N-acetylmuramyl-L-amino-butryl-D-isoglutamine. Clin. Exp. Metastasis. 2:1984;366-367.
86. Lotan R., Raz A. Endogenous lectins as mediators of tumor cell adhesion. J. Cell Biochem. 37:1988;107-117.
87. MacEwen E.G., Kurzman I.D., Rosenthal R.C., Smith B.W., Mainley P.A., Roush J.K., Howard E.H. Therapy for osteosarcoma in dogs with intravenous injection of liposome encapulsated muramyl tripeptide. J. Natl. Cancer Inst. 81:1989;935-938.
88. Maeda M., Knowles R.D., Kleinerman E.S. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 3:1991;313-321.
89. Malkovska V., Sondel P.M., Malkovsky M. Tumor immunotherapy. Curr. Opin. Immunol. 1:1989;883-890.
90. Mantovani A. Tumor-associated macrophages. Curr. Opin. Immunol. 2:1990;689-694.
91. Mantovani A., Bottazzi B., Colatta F., Sozzani S., Ruco L. The origin and function of tumor associated macrophages. Immunol. Today. 13:1992;265-270.
92. Martin D.W., Reece M., Reese A.C. Effect of plasma fibronectin, macrophages, and glycosaminoglycans on tumor cell growth. Cancer Invest. 2:1984;339-345.
93. Mosmann T.R., Coffman R.L. Th1 and Th2 cells. different patterns of lymphokine secretion lead to different functional properties Annu. Rev. Immunol. 7:1989;145-173.
94. Murray J.L., Kleninerman E.S., Cunningham J.E., Tatom J.R., Andrejcio K., Lepe-Zungia J., Lamki L.M., Rosenblum M.G., Frost H., Gutterman J.U., Fidler I.J., Krakoff I.H. Phase I trail of liposomal muramyl-tripeptide-phosphatidylethanolamine [MTP-PE (Cgp19835a)] in cancer patients. J. Clin. Oncol. 7:1989;1915-1925.
95. Nabioullin R., Sone S., Mizuno K., Yano S., Nishioka Y., Haku T., Ogura T. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J. Leukoc. Biol. 55:1994;437-442.
96. Nathan C.F. Secretory products of macrophages. J. Clin. Invest. 79:1987;319-326.
97. Nicolson G.L. Generation of phenotypic diversity and progression in metastatic tumors. Cancer Metastasis Rev. 3:1984;25-42.
98. Nii A., Utsugi T., Fan D., Denkins Y., Pak C., Brown D., van Hoogevest P., Fidler I.J. Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. J. Immunother. 10:1991;236-246.
99. Nishioka Y., Sone S., Orino E., Nii A., Ogura T. Down-regulation by interleukin-4 of activation of human alveolar macrophages to the tumoricidal state. Cancer Res. 51:1991;5526-5531.
100. Normann S.J. Macrophage infiltration and tumor progression. Cancer Metastasis Rev. 4:1985;277-291.
101. O'Brien T., Cranston D., Fuggie S., Bicknell R., Harris A.L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55:1995;510-513.
102. Pace J.L. Synergistic interactions between IFN-τ and IFN-β in priming murine macrophages for tumor cell killing. J. Leukoc. Biol. 44:1988;514-520.
103. Pak C.C., Fidler I.J. Activated macrophages distinguish undifferentiated-tumorigenic from differentiated-nontumorgenic murine erythroleukemia cells. Differentiation. 41:1989;49-55.
104. 14C-labelled) in the mouse. Int. J. Immunopharmacol. 1:1979;35-41.
105. Phillips N.C., Tsao M.S. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 49:1989;936-939.
106. Phillips N.C., Mora M.L., Chedid L., Lefrancier P., Bernard J.M. Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 39:1985;2582-2590.
107. Pizzo P.A. Granulocytopenia and cancer therapy. Past problems, current solutions and future challenges. Cancer. 54:1989;2649-2661.
108. Pohajdak B., Lee K., Sugawara I., Miller V., Wright J.A., Greenberg A.H. Comparative analysis of natural killer cell and macrophage recognition of concanavalin A-resistant Chinese hamster ovary cells. role of membrane oligosaccharides J. Natl. Cancer Inst. 2:1986;257-267.
109. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature. 283:1980;139-146.
110. Poste G., Kirsh R., Fidler I.J. Cell surface receptors for lymphokines. Cell. Immunol. 44:1979;71-88. a.
111. Poste G., Kirsh R., Fidler I.J. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Cancer Res. 39:1979;2582-2590. b.
112. Prehn R.T. The immune reaction as a stimulator of tumor growth. Science. 176:1972;170-171.
113. Ratner S., Schroit A.J., Vinson S.B., Fidler I.J. Analogous recognition of phospholipids by insect phagocytes and mammalian macrophages. Proc. Soc. Exp. Biol. Med. 182:1986;272-276.
114. Raynor R.H., Reese A.C. Effect of fibronectin on macrophage-induced tumor cell cytostasis. Oncology. 41:1984;420-426.
115. Raz A., Bucana C., Fogler W.E., Poste G., Fidler I.J. Biochemical, morphological and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41:1981;487-494.
116. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion. LRGD and integrins Science. 238:1987;491-497.
117. Russell P.I., Phillips J., Allan W., Hume D.A. Antigenic variation and macrophage infiltration of human bladder tumors xenografted into nude mice. J. Leukoc. Biol. 43:1988;335-342.
118. Russell S.W., Gillespie G.Y. Nature, function and destruction of inflammatory cells in regressing and progressing Moloney sarcomas. J. Reticuloendothel. Soc. 22:1977;159-168.
119. Saiki I., Dunegan M.A., Fann A.V., Koff W.C. Regulatory effects on macrophages of human recombinant interferons-α J. Interferon Res. 6:1986;603-611. a.
120. Saiki I., Milas L., Hunter N., Fidler I.J. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Cancer Res. 46:1986;4966-4970. b.
121. Schroit A.J., Fidler I.J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42:1982;161-167.
122. Schroit A.J., Hart I.R., Madsen J., Fidler I.J. Selective delivery of drugs encapsulated in liposomes. natural targeting to macrophages involved in various disease states J. Biol. Response Modif. 2:1983;97-100.
123. Schroit A.J., Madsen J.W., Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 260:1985;5131-5138.
124. Sone S., Tsubura E. Human alveolar macrophages. potentiation of the tumoricidal activity by liposome-encapsulated muramyl-dipeptide analogs J. Immunol. 129:1982;1313-1317.
125. Talmadge J.E., Key M., Fidler I.J. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J. Immunol. 126:1981;2245-2248.
126. Talmadge J.E., Schneider M., Collins M., Phillips H., Herberman R.B., Wiltrout R.H. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J. Immunol. 135:1985;1477-1483.
127. Tanaka Y., Schroit A.J. Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells. Recognition by autologous macrophages. J. Biol. Chem. 258:1983;11335-11341.
128. Tannenbaum C.S., Wicker N., Armstrong D., Tubbs R., Finke J., Bucowski R.M., Hamilton T.A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:1996;693-699.
129. Tanguay S., Bucana C.D., Wilson M.R., Fidler I.J., von Eschenbach A.C., Killion J.J. In vivo modulation of macrophage tumoricidal activity by the oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Cancer Res. 52:1994;5882-5888.
130. Thrombe P., Deodhar S.D. Inhibition of liver metastasis in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine. Cancer Immunol. Immunother. 16:1984;145-150.
131. Utsugi T., Dinney C.P.N., Killion J.J., Brown D., Fidler I.J. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res. 10:1991;487-493. a.
132. Utsugi T., Dinney C.P.N., Killion J.J., Fidler I.J. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol. Immunother. 33:1991;375-381. b.
133. Utsugi T., Schroit A.J., Conner J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51:1991;3062-3066. c.
134. Xu L., Fidler I.J. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol. Immunother. 18:1984;118-122.
135. Zwaal R.F.A., Hemker H.C. Blood cell membranes and haemostasis. Haemostasis. 11:1982;12-39.